EdiGene adds lab, office space for R&D center

By The Science Advisory Board staff writers

November 2, 2021 -- Biotech company EdiGene has signed a lease for 14,000 sq ft of lab and office space for its U.S. R&D center in the greater Boston area.

The center will work to translate EdiGene's gene editing technologies into new therapies for serious genetic diseases and cancer, according to the vendor.

EdiGene raises $62M to expand gene editing technologies
Biotech company EdiGene has raised $62 million in financing to expand its genome editing technologies and to accelerate drug discovery and therapies.
EdiGene, Immunochina to develop CAR-T therapy
EdiGene and Immunochina have announced they are collaborating on the development of allogeneic CAR-T therapy for cancer.

Copyright © 2021 scienceboard.net

HPLC 2022
June 18-23
San Diego, California United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter